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BACKGROUND: In human body fluids, microRNA
(miRNA) can be found as circulating cell-free miRNA
(cfmiRNA), as well as secreted into extracellular vesicles
(EVmiRNA). miRNAs are being intensively evaluated as
minimally invasive liquid biopsy biomarkers in patients
with cancer. The growing interest in developing clinical
assays for circulating miRNA necessitates careful consid-
eration of confounding effects of preanalytical and ana-
lytical parameters.
METHODS: By using reverse transcription quantitative
real-time PCR and next-generation sequencing (NGS),
we compared extraction efficiencies of 5 different proto-
cols for cfmiRNA and 2 protocols for EVmiRNA isola-
tion in a multicentric manner. The efficiency of the dif-
ferent extraction methods was evaluated by measuring
exogenously spiked cel-miR-39 and 6 targeted miRNAs
in plasma from 20 healthy individuals.
RESULTS: There were significant differences between the
tested methods. Although column-based extraction
methods were highly effective for the isolation of endog-
enous miRNA, phenol extraction combined with
column-based miRNA purification and ultracentrifuga-
tion resulted in lower quality and quantity of isolated
miRNA. Among all extractionmethods, the ubiquitously
expressed miR-16 was represented with high abundance
when compared with other targeted miRNAs. In addi-
tion, the use of miR-16 as an endogenous control for
normalization of quantification cycle values resulted in a
decreased variability of column-based cfmiRNA extrac-
tion methods. Cluster analysis of normalized NGS
counts clearly indicated a method-dependent bias.
CONCLUSIONS: The choice of plasma miRNA extraction
methods affects the selection of potential miRNAmarker
candidates and mechanistic interpretation of results,
which should be done with caution, particularly across
studies using different protocols.
© 2019 American Association for Clinical Chemistry
In the past decade, molecular analysis of circulating nu-
cleic acids in body fluids started to have a growing impact
on the clinical treatment of patients with cancer. Liquid
biopsy is a rapidly expanding field in translational cancer
research and shows the potential to complement diagnos-
tic and therapeutic care of patients with cancer.
Circulating biomarkers, including cancer-derived
microRNA (miRNA),12 have emerged as a new class of
promising minimally invasive clinical biomarkers for liq-
uid molecular profiling of patients with cancer (1–4).
miRNAs are short (about 22 nucleotides in length) non-
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coding RNAs that regulate protein-coding gene expres-
sion by binding to a specific site in the 3 untranslated
regions of mRNA targets and, thus, promote their deg-
radation and/or translational inhibition, thereby poten-
tially contributing to cancer initiation and progression.
The use of miRNA in body fluids as biomarkers may be
associated with a number of advantages: (a) cell-free
miRNA (cfmiRNA) is well-preserved in body fluids ow-
ing to an association with Argonaute 2 protein (5, 6 ) or
high-density proteins (7 ); (b) extracellular vesicles (EVs),
primarily exosomes, have been identified as important
carriers for miRNA, keeping RNAs protected from inter-
cellular nucleases (8, 9 ); and (c) circulating miRNA is
highly stable over multiple freeze–thaw cycles, long-term
storage, or treatment with RNase (10 ). Therefore, a
number of extraction methods for miRNA have been
developed and commercialized in the past decade. Asso-
ciated with this is the need for appropriate controls of
preanalytic and analytic variables when considering cir-
culating miRNA biomarkers in the clinical setting (11–
13). Analytical challenges such as low concentration,
suboptimal RNA integrity, and high interindividual vari-
ability of miRNA expression must be controlled to estab-
lish clinically deployable miRNA biomarker assays. In
addition, methods for the isolation of EVs differ in sub-
populations, size, concentration, purity, and functional-
ity of the extracted EVs (14 ). Therefore, selecting appro-
priate extraction methods is a critical step in all areas of
miRNA liquid biopsy research. Finally, standardization
and benchmarking of downstream read-out technologies
are of key importance to generate comparable data
among different analytical laboratories or among differ-
ent clinical studies.
Within the Innovative Medicines Initiative project
CANCER-ID, standardization of preanalytical and ana-
lytical work flows for blood-based biomarkers is a key
objective. Here, we report the results on the implemen-
tation of different miRNA extraction technologies in a
multicentric ring study to establish standardized analyti-
cal work flows for plasma-derived miRNA analysis. Five
different miRNA and 2 EV miRNA (EVmiRNA) isola-
tion protocols were systematically compared in the study
by using reverse transcription quantitative real-time PCR
(RT-qPCR) and next-generation sequencing (NGS).
The candidate miRNAs miR-16, miR-21 [reviewed by
Bica-Pop et al. (15 )], let-7a, and miR-191 were chosen
not only because of their ubiquitous expression in a wide
range of body fluids (16, 17 ) and their potential role as
cancer biomarkers, but also because of ongoing discus-
sion about their suitability for normalization (14 ). In
addition, the EV-associatedmiRNA candidates miR-122
(predominantly found outside of EVs) and the EV-
associatedmiR-150 (highly enriched inEVs)were included.
Materials and Methods
STUDY DESIGN
For this study, 10 mL of K2EDTA whole blood from 20
healthy donors (10 female, 62.6 6.9 years of age; 10male,
60.3 5.6 years of age) was collected at the Zitha Clinic in
Luxembourg under the Informed Consent CNER
201005/02 (approved by the local Luxembourg ethics com-
mittee) and processed to plasma at Integrated BioBank
of Luxembourg. Systematic comparison of different
extraction protocols for cfmiRNA and EVmiRNA
from plasma was designed as a multicentric ring study.
Six commercially available extraction kits and ultra-
centrifugation were performed by six CANCER-ID
participating sites. The extracted miRNA was centrally
analyzed using miScript qPCR and miRNA QIAseq
(QIAGEN) (see Fig. 1 in the Data Supplement that
accompanies the online version of this article at
http://www.clinchem.org/content/vol65/issue9).
PLASMA PROCESSING
Blood samples (10mL) fromall blooddonorswere obtained
by venipuncture.Bloodwas collected inK2EDTAvacutain-
ers (BD). Blood tubes remained at ambient temperature
until plasma was generated within 4 h after blood draw.
Plasma samples were centrifuged at 1900g for 10 min at
4 °C. Supernatant was carefully transferred into 15-mL
high-performance centrifuge tubes (VWR) and centrifuged
a second time at 16000g for 10 min at 4 °C to remove
cellular debris. From each tube, 4 mL of plasma was ali-
quoted in 2 portions of 2 mL, which were shipped to Bayer
AG on dry ice; one freeze–thaw cycle was done while pre-
paring the aliquots. Bayer AG prepared aliquots of the
plasma samples depending on the extraction methods
(Table 1).
EXOGENOUS CONTROL
Synthetic cel-miR-39 (Caenorhabditis elegans; 5-
UCACCGGGUGUAAAUCAGCUUG-3) (QIAGEN)
was added to each extraction. Ten picomoles of lyophilized
synthetic cel-miR-39 was dissolved in 550 L of nuclease-
free water resulting in a 1E10 copies/L stock solution.
Every participating site added 52.5 L into the method-
specific lysis buffer (volume according to vendor specifica-
tions). Based on this, the total amount spiked into the
cDNA synthesis was 4.5 fmol for each extraction method.
Adding 200LofRNase-freewater to the reverse transcrip-
tion reaction resulted in a cel-miR-39 concentration of
2.8E07 copies/L in each qPCR reaction. For ultracen-
trifugation, the spike-in was added at the EV lysis step and,
therefore, does not reflect efficiency of the EV isolation step.
ISOLATION OF cfmiRNA
cfmiRNA was isolated from 200 L of plasma using five
commercially available extraction technologies (Table 1).
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Isolation was performed following manufacturers’ rec-
ommendations. Total RNA, including cfmiRNA, was
eluted in 100 L of mirVana (mirV), 50 L of
miRCURY Biofluids (miRCB), 15 L of Plasma/Serum
RNA Purification Mini (PSRPM), and 14 L of
[miRNeasy Serum/Plasma (miRSP), miRNeasy Ad-
vanced Serum/Plasma (miRA)] nuclease-free water.
ISOLATION OF EVmiRNA
EVmiRNA was isolated from 1 mL of plasma using the
exoRNeasy Serum/Plasma Midi [exoRNeasy Serum/
Plasma (exoR)] kit (QIAGEN), which was performed
according to the manufacturer’s recommendations, and
eluted in 14L of nuclease-free water. EV isolation using
ultracentrifugation followed by membrane affinity
miRNA extraction (Table 1) was performed as detailed
below.
ULTRACENTRIFUGATION STEP
EDTAplasma samples (1mLeach)were thawed at 37 °C in
a water bath and placed on ice. Samples were diluted 1:2
with cold sterile-filtered PBS (0.2 m,Whatman TM, GE
Healthcare Life Sciences). After gentle mixing by inversion,
diluted plasma samples were filtered with 0.8-m Millex
AA syringe filters (MerckMillipore). EVswere thenpelleted
by ultracentrifugation at 100000g (K-factor, 123.0) for 2 h
using a fixed-angle rotor TLA-55 (Beckman-Coulter) at
4 °C. The supernatant was carefully aspirated by pipetting,
and each pellet was resuspended in 50Lof ice-cold filtered
PBS. EVs were frozen at80 °C until use.
RNA EXTRACTION STEP
Total RNA was extracted from frozen EV concentrates
with the miRNeasy Micro kit (QIAGEN) according to
the manufacturer’s protocol “Purification of Total RNA,
Including miRNA, from Animal Cells.” ADNase I treat-
ment was not performed. Total RNA, including
EVmiRNA, was eluted in 14L of RNase-free water and
stored at 80 °C until use.
REVERSE TRANSCRIPTION
cDNA was generated from extracted cfmiRNA and
EVmiRNA samples using the miScript II RT kit
(QIAGEN), according to the manufacturer’s instruc-
tions. Ten percent of each eluate {i.e., 10 L [mirV], 5
L [miRCB], 1.5 L [PSRPM], and 1.4 L [miRSP,
miRA, exoR, exosome ultracentrifugation (exoU)]} was
used for the cDNA synthesis in a 20-L reaction using
the miScript HiSpec buffer (QIAGEN). The reactions
were incubated for 60min at 37 °C and stopped at 95 °C
for 5 min. Finally, cDNA was diluted in 200 L of
nuclease-free water.
QUANTITATIVE REAL-TIME PCR
Real-time PCR was carried out using the miScript
SYBR Green PCR kit (QIAGEN) on a CFX-96 real-
time PCR detection system (Bio-Rad Laboratories) ac-
cording to the manufacturer’s instructions. Twenty-
five microliters of PCR reaction mix included 2.5 L
of prediluted cDNA, 12.5 L of QuantiTect SYBR
Green PCR Master Mix, 2.5 L of miScript Universal
Primer, and 7.5 L of nuclease-free water. The reac-
tion mixture was added to a custom miScript Primer
Assay plate containing the lyophilized miRNA-
specific primer assays for one 25-L real-time PCR
reaction/well. Besides selected miRNA-specific primer
assays (let-7a-5p, miR-150–5p, miR-16–5p, miR-
122–5p, miR-21–5p, miR-191–5p), several control
Table 1. RNA extraction kits utilized in this study and participation site.
Extraction site Manufacturer RNA extraction kit/protocol Abbreviation Principle of extraction
University of Athens Thermo Fisher
Scientific
mirVana mirV Phenol + spin column
IBBL QIAGEN miRNeasy S/P miRSP Phenol + spin column
QIAGEN QIAGEN miRNeasy Advanced S/P miRA Protein precipitation +
spin column
TATAA Norgen P/S RNA Purification Mini PSRPM Proteinase K + spin
column
Bayer AG Exiqon miRCURY Biofluids miRCB Protein precipitation +
spin column
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primer assays were included: cel-miR-39–3p, positive
PCR controls (PPCs) in duplicates, and miRNA re-
verse transcription control (miRTC) in triplicates.
Samples were incubated at 95 °C for 15 min, followed
by 40 amplification cycles of 94 °C for 15 s, 55 °C for
30 s, and 70 °C for 30 s. The ramp rate of the instru-
ment was set at 1 °C/s. A melt curve analysis was
performed following PCR cycling. The quantification
cycle (Cq) value was defined using the regression
mode.
NGS
NGS libraries were prepared from 5-L aliquots using
the QIAseq miRNA Library kit (QIAGEN). A detailed
description of the libraries and NGS procedure is pro-
vided in Materials and Methods of the online Data
Supplement.
RT-qPCR AND NGS DATA NORMALIZATION
Raw Cq values of targeted miRNA were normalized to
the endogenous miR-16 (16 ) and to the spiked-in cel-
miR-39 (12 ):
Targetnormalized  Targetraw
 (Controlraw  Controlmedian run) (1)
where Target is the miRNA to be normalized, Control is
miR-16 or cel-miR-39, raw is the sample Cq value, and
median run is the median Cq value of 20 raw results
produced by each technology. To this end, the standard
variation was calculated from raw and normalized Cq
values (Tables 2 and 3).
NGS data were preprocessed and analyzed using the
MultiD GenEx software 7.0.1.473. Data normalization
consisted of the following steps: (a) miRNA without any
Table 2. Mean Cq values SD of 6 human miRNAs measured by RT-qPCR in 20 healthy individuals.
Normalized to
cel-miR-39 miR-16
Mean raw Cq SD raw Cq Cq SD Cq %
a Cq SD Cq %
a
let-7a 27.76 1.67 27.73 1.59 4.79 27.68 1.67 0.00
miR-16 24.15 1.48 24.12 1.50 −1.35 — — —
miR-21 26.98 1.74 26.95 1.17 32.76 26.91 1.80 −3.45
miR-122 30.23 2.43 30.20 2.39 1.65 30.16 2.49 −2.47
miR-150 27.49 1.73 27.46 1.67 3.47 27.42 1.81 −4.62
miR-191 29.45 1.81 29.42 1.95 −7.73 29.37 1.79 1.10
a Percentages indicate the proportion of normalized SD of Cq values relative to raw SD of Cq values.
Table 3. Mean Cq values and SD of different RNA extraction protocols.
Normalized to
cel-miR-39 miR-16
Code Mean raw Cq
a SD raw Cq Cq SD Cq %
b Cq SD Cq %
b
mirV 28.00 2.14 27.65 2.20 −2.80 28.23 2.10 4.55
miRCB 26.39 2.13 26.67 2.26 −6.10 27.12 1.70 24.78
miRSP 29.14 2.69 29.21 2.58 4.09 29.92 1.87 27.52
miRA 26.61 2.47 26.24 2.43 1.62 27.37 1.65 32.10
PSRPM 27.84 2.24 27.88 2.22 0.89 28.58 1.34 39.64
exoR 26.80 3.18 26.9 3.11 2.20 27.38 3.11 0.00
exoU 28.98 2.25 28.98 2.24 0.44 29.55 2.15 4.02
a Mean Cq for all the miRNA tests by method.
b Percentages indicate the proportion of normalized SD of Cq values relative to raw SD of Cq values.
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counts in all samples were removed; (b) all remaining values
were converted to log2; (c)missing valueswere replacedwith
1; and (d) data were normalized to total number of counts.
STATISTICAL ANALYSIS
The R (version 3.5.2) and R Studio software (R Studio)
were used for statistical analysis and data visualization. Sta-
tistical comparisons were performed using Student t-test.
Two-sided tests with P 0.05 were considered statistically
significant.Correlationswere calculatedusingPearson rank.
Principal component analysis (PCA) of normalized NGS
data was done using the t-test method with autoscaling of
the column-wise scaling in the PCA step. Visualization of
results in box plots, histogram, and PCA plot and heatmap
was carried out using the package ggplot2.
Results
miRCB AND miRA EXTRACTED THE HIGHEST AMOUNTS OF
ENDOGENOUS CANDIDATE miRNAS
First, total RNA, including cfmiRNA and EVmiRNA,
was characterized by a customized miScript PCR panel
including six different miRNA targets and distinct con-
trol targets. The inhibition control showed with a mean
Cq
PPC value of 18.78 high-quality RNA across all extrac-
tion kits. In addition, Cq values of the miRTCs were
examined using the values for the PPCs by calculating
Cq  meanCq
miRTC  meanCq
PPC revealing a mean
value of 3.49 across all extraction kits, which indicated no
inhibition of the reverse transcription reaction. Further,
cel-miR-39 levels were evaluated (Fig. 1A). Recovery of
cel-miR-39 in each case was estimated with respect to Cq
values, thus translating lower Cq values into higher recov-
ery of cel-miR-39.
In more detail, the miRSP (mean Cq, 20.87 0.67)
and the miRA (mean Cq, 21.24 1.28) revealed signif-
icantly [P  0.001 (miRSP), P  0.00133 (miRA)]
highermeanCq values comparedwith the basemean (Cq,
20.13) among five cfmiRNA extraction methods. The
mirV (mean Cq, 20.05  0.62) and the PSRPM (mean
Cq, 19.78 0.52) were slightly lower than the cfmiRNA
base mean, whereas the miRCB (mean Cq, 18.68 
0.53) showed a significantly (P 0.0001) lowermeanCq
value.Moreover, with the exoR (meanCq, 17.43 0.63)
Fig. 1. Column-based RNA extraction technologies reveal high recovery of exogenous and endogenous miRNAs.
(A), Box plot analysis showing recovery of synthetic spiked-in cel-miR-39 among commercially availablemiRNA extraction technologies.
Each dot represents a single plasma sample. (B), Box plot analysis showing 6 different targeted miRNAs to compare the extraction
efficiency of 5 total RNA and 2 EVmiRNA extraction methods: miRCB, dark blue; mirV, red; miRSP, yellow; miRA, brown; PSRPM, gray;
exoR, dark green; and ultracentrifugation followed by the exoU, light green. (C), Bee swarm plot analysis showing each extraction
method among targeted miRNAs. The resulting miRNA quantity is reported as raw Cq value. The horizontal line in each box represents
the mean; the error bars indicate the range; statistical analysis in (A) and (C) was performed using Student t-test with the base mean
(dotted line) to compare all groups where *P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001.
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slightly lower and with the exoU (mean Cq, 18.05 
0.56) slightly higher Cq values compared with the base
mean (Cq, 17.74) of EVmiRNA extraction protocols
were observed.
Next, Cq values of targeted miRNA were evaluated.
Each extracted miRNA was detected in varying amounts
dependent on the extraction technology and site (Fig. 1B
and Table 2). Importantly, differences up to 3 Cq values
were shown between different extraction sites (Figs. 1B and
2). In addition, miRNA amounts showed a high interindi-
vidual variability, which was also influenced by the isolation
method. miR-16 exhibited the highest expression (mean
Cq, 24.15) and marginal variability (SD, 1.48) among all
targeted miRNAs and extraction technologies. In addition,
miR-21 was found highly expressed (mean Cq, 26.98 
1.74).
Subsequently, amounts of all miRNA targets were
evaluated with respect to the extraction protocol (Fig. 1C
and Table 3). The miRCB displayed the lowest overall
meanCq value of 26.4 for the six selectedmiRNA targets.
With a Cq value of 26.6, the mean amount of endoge-
nous miRNAs extracted with the miRA was similar. In
addition, both kits showed a significantly (P  0.001)
lower mean Cq value compared with the base mean (Cq,
27.59) among five cfmiRNA extractionmethods. In con-
trast, the mirV and PSRPM resulted in a mean Cq value
of 28.0 and 27.8, respectively, while the miRSP showed
the highest meanCq value (29.1), which was significantly
higher (P  0.0001) compared with the base mean.
For EV-derived miRNA fractionations, exoU
showed a significantly (P 0.001) higher mean Cq value
(29.0), whereas the exoR kit revealed a significantly (P
0.00196) lower mean Cq value (26.89) compared with
the base mean (Cq, 27.89) of EVmiRNA extraction pro-
tocols (Fig. 1C).
NGS ANALYSIS CONFIRMED HIGH EFFICIENCY AND
ANALYTICAL PERFORMANCE OF THE miRCB AND miRA
Total RNA extractionmethods were compared by applying
the QIASeq miRNA library kit. The mapping distribution
of different smallRNAs is shown inFig. 3 of the onlineData
Supplement. Box plot analysis (Fig. 3A) shows the total
mappedmiRNAreadnumber in 20healthy donors for each
of the 7 RNA extraction protocols. Sequencing of miRNA
resulted in a base mean of 2.89E06 and 1.55E06 reads
for miRNA and EVmiRNA extraction protocols, respec-
tively. ThemiRCB showed significantly (P 0.001) higher
reads (mean total reads, 3.73E06) compared with the
othermiRNAprotocols. Comparing EVmiRNA extraction
protocols, the exoR revealed significantly (P  0.0036;
mean total reads, 2.35E06) higher and the exoU signifi-
cantly (P  0.0001; mean total reads, 7.65E05) lower
read numbers. Supporting the RT-qPCR results, miR-16
displayed the highest uniquemolecular index (UMI) counts
across all extraction technologies (Fig. 3B). miRNAs were
distributed with heterogeneous mean counts among 20
healthy individuals dependingon the extraction technology.
In addition, a strong read repetition revealed that miRCB
Fig. 2. Multicentric evaluation of RNA extraction technologies shows variability between extraction sites and kits.
Box plot analysis showing six different targetedmiRNAs to compare the extraction efficiencies between different extraction sites and kits. The
horizontal line in each box represents the mean; the error bars indicate the range. IBBL, Integrated BioBank of Luxembourg.
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and miRA showed most cumulative miRNA molecules
(Fig. 3C). This was not a consequence of more allocated
total reads:While having the highest (miRCB, 39%;miRA,
34%)miRNAmolecule counts, either similar or fewer total
reads allocated during sequencing compared with the other
protocols were obtained (Fig. 3A). Surprisingly, both exoR
andexoUproduced37%and48%, respectively, cumulative
“too short” reads and fewer mapped miRNA molecules
(Fig. 3C).
Moreover, we compared normalized total read
counts produced by each extraction protocol. Global
clustering by PCA clearly indicated distinct groups
(bias) introduced by the miRNA purification methods
(Fig. 3D). Four groups can be visually distinguished:
(a) exoU, (b) PSRPM, (c) mirV, and (d) exoR, miRCB,
miRA, and miRSP. Ultimately, we compared the Cq
values and normalized UMI reads among all endoge-
nous miRNAs. The correlation heatmap shown in Fig.
3E demonstrated an inverse correlation (r 	 0.5)
between RT-qPCR and NGS results for all extraction
protocols. The strongest correlation was shown for the
miRCB (r0.728). Interestingly, the cluster illustrated
that EVmiRNA-determined Cq values only slightly corre-
lated with UMI reads for cell-free RNA. Conversely,
EVmiRNA-based UMI reads were strongly correlated with
Cq values obtained for cell-free miRNA.
NORMALIZATION WITH ENDOGENOUS miR-16 DECREASED
VARIABILITY OF COLUMN-BASED KITS
Mean raw Cq values of each targeted miRNA and ex-
traction technology were normalized to cel-miR-39 or
miR-16 (Tables 2 and 3). With the exception of
miR-21 (32.8% decreased SD compared with raw Cq
value SD), normalization to cel-miR-39 had no influ-
ence on variability of mean raw Cq values of each
candidate miRNA among all extraction kits. In addi-
tion, normalization to miR-16 increased variability of
candidate miRNAs (Table 2).
Interestingly, using miR-16 to normalize mean raw
Cq values of each extraction kit among all candidate
miRNAs (Table 3), we observed a decreased Cq value
variability of column-based kits (miRCB, miRSP, miRA,
and PSRPM) of 24.78%, 27.53%, 32.10%, and
39.64%, respectively. Normalization to cel-miR-39 left
the variability largely unchanged or even increased it.
Fig. 3. Small RNA sequencing confirms high performance of miRCB and miRA isolation kits.
(A), Box plot analysis showing total reads among commercially available miRNA extraction technologies. Each dot represents one plasma
sample. (B), Box plot analysis showing total counts of each endogenous miRNA among all technologies. The horizontal line in each box
represents themean; the error bars indicate the range; statistical analysis in (A)was performedusingStudent t-testwith thebasemean (dotted
line) to compare all groups where **P < 0.01, ***P < 0.001, and ****P < 0.0001. (C), Bar plot showing the percentage of cumulative
mapping of miRNA raw reads and “too short” (<16 bp insert sequences) reads. (D), PCA of miRNA data generated by NGS distinguishes four
groups: (a) exoU, (b) PSRPM, (c) mirV, and (d) exoR, miRCB, miRA, andmiRSP. The contribution of PC1 and PC2 to the overall variance in the
data set is 61.9% and 4.53%, respectively. (E), Correlation matrix of extraction methods used in this study. Results of qPCR and NGS were
compared. Correlation coefficients are color-coded in red (r<−0.5), white (r=−0.5) and blue (r>−0.5).
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Discussion
Notwithstanding the growing number of published cir-
culatingmiRNA studies in patients with cancer (18–22),
there is still no consensus on procedures and standardized
protocols to use downstream analytical technologies, not
even with respect to preanalytical sample handling in the
clinical setting, which represents the first step in analyti-
cal work flows. In this study, we performed extraction
using seven protocols at six different participating sites.
Several research groups have investigated circulating
miRNA extraction by comparing different protocols
(12, 23–30). In our analysis, isolation of cfmiRNA based
on the miRCB and the miRA resulted in low Cq values
and high relative numbers of mapped miRNA reads over
“too short” reads. In addition, NGS reads showed a tight
cluster, as both column-based kits have a similar work
flow to precipitate proteins and purify miRNA from the
supernatant. It is important to note that after the acqui-
sition of Exiqon by QIAGEN, the miRCB is no longer
available. In contrast, the mirV and the PSRPM pro-
duced higher Cq values and a lower percentage ofmiRNA
raw reads compared with too short reads. Using the
miRSP, practical issues with phase separation in about
50% of samples occurred for unknown reasons. By dou-
bling the QIAzol and chloroform this could be solved;
however, only half of the doubled upper phase (600 L)
could be loaded in theQIAcube, resulting in a 1-Cq value
increase and a lower number of miRNA raw reads. Tak-
ing this technical issue into account, the results of this
study were comparable with another study (23 ), demon-
strating that RNA extraction with miRSP led to a 2- to
3-fold increase in RNA yield compared with the mirV
kit. In addition, several studies (24, 26, 27 ) showed a
high recovery of cfmiRNA using the miRSP. In our
hands, the miRCB outperformed other column-based
extraction technologies, which strengthens the results of
other studies (25, 30 ). In contrast, others (12, 28 ) found
that the mirV and the miRNeasy produced the highest
yield of recovery for spiked-in control miRNA, with the
mirV obtaining a better performance than the miR-
Neasy. Interestingly, the exoR and exoU were prone to
capture too short sequences. exoU revealed almost 50%
of too short miRNA reads, in line with a previous study
(14 ). NGS data obtained by different extraction proto-
cols and participation sites might be biased for a unique
subpopulation of miRNA. Highly abundant miRNA are
less affected by library preparation-induced biases, al-
though this might be more problematic for low-
abundance transcripts (14 ). One limitation of the study
is that we did not test each protocol at each site.However,
routinely used standard protocols for the extraction of
miRNA were used; in addition, experienced personnel
extracted the miRNA. Nevertheless, there is still a chance
that the performance of the protocol is influenced by the
operator rather than by its technical specifications.
Normalization of raw Cq values using the exogenous
cel-miR-39 left total variability unchanged. However, one
must be aware that heterogeneous cel-miR-39 recovery be-
tweenmethods,which areprobably introducedby spiked-in
variations (e.g., different pipette sets and operators), could
affect normalization. On the other hand, normalization to
endogenous miR-16, commonly reported as an miRNA
housekeeper (16, 17, 31), decreased the variability of
miRCB, miRSP, miRA, and PSRPM. Interestingly, the
SDs of themirV kit and both exoU and exoR kits remained
similar. These results are in contrast to another study (12),
illustrating an increase in variancewhenusingmiRNA-16as
a normalizing factor. Global clustering of normalized UMI
reads of endogenous miRNAs revealed a prominent cluster
of miRCB, miRSP, miRA, and exoR. It becomes clear that
every extraction method introduces a method-dependent
bias. In this context, it might be difficult to compare the
extraction kits, as there is no independent standard and ev-
ery method extracts a unique subpopulation of miRNA. In
addition, concerning the variability between extraction sites,
the difference between biological groups (e.g., cancer pa-
tients vs healthy) should be	2Cq values to overcome tech-
nical background noise. This underlines the fact that no
normalization approach will eliminate all sources of varia-
tion (e.g., blood storage). However, without standardiza-
tion, clinical application of miRNA will remain uncertain.
In conclusion, we report here that enriching cfmiRNA
by the miRCB and miRA allows high recovery of endoge-
nousmiRNA.Working toward standardization, all technol-
ogy providers should implement the possibility of analyzing
identical sets of artificial miRNAs (e.g., cel-miR-39, ath-
miRs) including variants and modifications; all biobanks
should pay attention to developments in the preanalytical
field to allow collection of samplesmost suitable formiRNA
analysis; and all laboratories should participate in external
quality assessment “processing” and analytical schemes to
assess the performance of their miRNA extraction meth-
od(s) and their relative or absolute quantification assays
and/or implement appropriate reference material. Our
study underpins the necessity of performing standardized
benchmarking studies to implement best practices of extrac-
tion and analysis platform performance formiRNA analysis
in liquid biopsy.
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